Treatment selection in advanced breast cancer is based on a patient’s and disease characteristics, including, among others, tumor burden, previous treatments, and tumor phenotype, in particular estrogen and progesterone receptor expression and HER2 status [3]. Here, ERBB2 is linked to breast cancer.